IL6 and COVID-19: Based on these evidences, understanding the consequences of the concomitant presence of risks factors (IL-6 + AZM + HCQ) on the arrhythmic risk, is urgently needed to inform the clinical decisions for not only COVID-19 patients but also for patients with other autoimmune/inflammatory conditions.